← Back to Search

CAR T-cell Therapy

Neuropsychological Testing for Aggressive Lymphoma

N/A
Waitlist Available
Led By Brian Scott, MD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age >/= 18 years-old
Able to attend and participate in in-person testing (Arm I)
Must not have
Unable to participate in testing due to severe cognitive or physical limitation
Actively receiving chemotherapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights
No Placebo-Only Group

Summary

This trial will test if a new cancer treatment improves the thinking skills of patients.

Who is the study for?
This trial is for adults over 18 who've had Axicabtagene ciloleucel CAR-T therapy for aggressive lymphoma. Participants must be fluent in English, able to attend in-person or remote testing with good internet and a computer, and at least 6 months post-CAR-T infusion. Those with severe cognitive/physical limitations, active chemotherapy treatment, progressive cancer, or enrolled in another CAR-T study can't join.
What is being tested?
The study is evaluating the long-term effects of CAR-T therapy on brain function by using neuropsychological tests. It will measure how well participants think and process information after their treatment at Stanford.
What are the potential side effects?
Since this trial involves neuropsychological testing rather than drug interventions, there are no direct side effects from medications being studied. However, the process may cause fatigue or stress.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I can go to the clinic for tests.
Select...
It has been 6 months or more since my CAR-T cell therapy.
Select...
I have received Axicabtagene ciloleucel CAR-T therapy.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot take part in tests due to severe mental or physical limitations.
Select...
I am currently undergoing chemotherapy.
Select...
I cannot attend the scheduled tests.
Select...
My cancer is getting worse.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Clock Drawing Test
Controlled Oral Work Association Test COWAT
Digit Span
+6 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Neuropsychological testingExperimental Treatment1 Intervention
Participants will take neuropsychological testing in-person or via telehealth video
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Neuropsychological testing
2017
N/A
~570

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,491 Previous Clinical Trials
17,519,233 Total Patients Enrolled
Brian Scott, MDPrincipal InvestigatorStanford University

Media Library

Axicabtagene ciloleucel (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05416554 — N/A
Non-Hodgkin's Lymphoma Research Study Groups: Neuropsychological testing
Non-Hodgkin's Lymphoma Clinical Trial 2023: Axicabtagene ciloleucel Highlights & Side Effects. Trial Name: NCT05416554 — N/A
Axicabtagene ciloleucel (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05416554 — N/A
~13 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top